Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.42 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19848593 | 0.87 | GRM2 (0.42) | GRM2PTK2ARRAB9ASMN1; SMN2 | |
| SCHEMBL19848208 | 0.81 | KDM4E (0.46) | GRM2ALDH1A1HCAR3RAB9ASMN1; SMN2 | |
| SCHEMBL19848519 | 0.81 | NAMPT (0.43) | KCNMA1HCAR3RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL203857 | 0.81 | SLC9A1 (0.44) | GRM2KCNMA1HCAR3PTK2RAB9A | |
| SCHEMBL19915658 | 0.80 | PKM (0.55) | GRM2KCNMA1ALDH1A1HCAR3SMN1; SMN2 | |
| SCHEMBL15822183 | 0.78 | HCAR3 (0.38) | HCAR3RAB9ASMN1; SMN2 | |
| SCHEMBL19911624 | 0.78 | GRM2 (0.47) | GRM2KCNMA1ALDH1A1HCAR3PTK2 | |
| SCHEMBL18323591 | 0.78 | HCAR3 (0.58) | GRM2KCNMA1ALDH1A1HCAR3RAB9A | |
| SCHEMBL15822868 | 0.77 | PRKDC (0.39) | ALDH1A1HCAR3GLARAB9ASMN1; SMN2 | |
| SCHEMBL19911501 | 0.77 | MAPT (0.44) | ALDH1A1HCAR3PTK2RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| EP-3279997-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | Asahi Kasei Kabushiki Kaisha (JP) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | GRM2 2693/4885KCNMA1 525/4885ALDH1A1 3497/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | GRM2 2693/4885KCNMA1 525/4885ALDH1A1 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.